深度报告-2025-11-20-Citeline-2026年生物制药未来展望_45页_15mb

Biopharma Industry Analysis: 2025 Trends

1. Asia-Pacific Dominance in Innovation

• China has emerged as a global leader in biopharma R&D, with over 30% of active clinical trials being conducted by Chinese companies as of 2025. Key strengths include:

  • Oncology and rare diseases: Leading in CAR-T therapies, ADCs (ADCs dominate 53% of the global pipeline), and rare disease treatments (e.g., angiosarcoma).
  • Digital innovation: Companies like Insilico and Junshi Biosciences are leveraging AI for drug discovery, with AI-first strategies driving new modalities.
  • Mergers & Acquisitions (M&A): Cross-border deals (e.g., AstraZeneca partnering with Chinese firms) are accelerating, with foreign pharma firms increasingly outsourcing R&D and manufacturing to China.

• India:

  • Generic and biosimilar leadership: India remains a top supplier of affordable medicines, with 40% of global generic APIs and 20% of US generics demand met by Indian firms.
  • Manufacturing growth: India’s pharma exports to the US increased by $5.6bn in 2024, with 75% of APIs produced domestically. Digital health initiatives (e.g., prescription tracking) are improving compliance and reducing errors.
  • Regulatory reforms: The Indian government is pushing for CGT-specific regulations and centralized databases to streamline approvals and attract global partnerships.

• Japan and South Korea:

  • Japan: Focuses on advanced therapies (CAR-T, CGT), with domestic production capabilities being strengthened. METI allocated ¥38.3bn to support CGT CDMOs, aiming for a 20% global market share by 2033.
  • South Korea: Faces challenges in its clinical trial infrastructure due to regulatory ambiguity and cultural barriers, but is adopting AI for drug development and exploring decentralized trials.

2. Key Therapeutic Areas

• Oncology: ADCs, bispecific antibodies, and CAR-T therapies are driving innovation. Chinese firms lead in ADC development (e.g., Junshi’s JS207, Mabwell’s BFv), while global players like Merck & Co. and Pfizer are partnering with Chinese biotechs.
• Rare Diseases: China is a pioneer in angiosarcoma treatments, with companies like Renascience and Stella Pharma leading. India is focusing on orphan drugs through incentives and partnerships.
• Digital Health: GenAI is revolutionizing drug discovery (e.g., Insilico, Xeureka’s Tokyo-1 platform). AI is also being used for real-time diagnostics and clinical trial optimization.

3. Manufacturing and Supply Chain Dynamics

• China: Localization is accelerating due to US retaliatory tariffs, with Chinese firms gaining market share (e.g., 58% of US pharma imports now originate from China). Companies like Zai Lab are localizing production to reduce dependency on foreign partners.
• India: Manufacturing expansion is supported by government initiatives (e.g., BioE3 Policy), but challenges include AMR and funding constraints. APIs account for 35% of global volume, with India producing 40%.
• Japan and South Korea: Focus on high-value manufacturing (CGT, cell therapies), but Japan faces pressure from US tariffs. South Korea is diversifying into digital therapeutics (DTx) and exploring partnerships to offset R&D limitations.

4. Geopolitical and Regulatory Challenges

• US-China Trade War: Reciprocal tariffs (84% on US goods) have prompted Chinese firms to localize production and diversify portfolios. India and South Korea are attracting investments to mitigate supply chain risks.
• Regulatory Shifts:
  • China and India are enhancing expedited review programs (China’s NMPA granted 59 drugs for expedited review in H1 2025).
  • Japan and South Korea are integrating AI into regulatory processes, with Japan launching a “Guide” program for innovative products.

5. Emerging Modalities and Future Outlook

• Precision Oncology: ADCs, bispecific antibodies, and synthetic lethality drugs (e.g., PRMT5 inhibitors) are showing promise. Over 40% of the global pipeline targets solid tumors.
• Gene & Cell Therapy: India and Japan are competing to lead in CGT production, with India focusing on cost-effective manufacturing and Japan emphasizing quality control.
• AI and Automation: Digital tools are reducing R&D timelines by 90% in some cases, with global pharma firms investing in AI-powered CDMOs (e.g., Roivant Sciences).

6. Market Opportunities and Recommendations

• For Global Sponsors: South Korea offers fast regulatory approvals (112 days for trial start-up), making it attractive for early-phase studies. India and China provide access to large patient populations and lower-cost manufacturing.
• Pharma Companies: Leverage digital partnerships to accelerate R&D, diversify manufacturing, and navigate trade disputes. Focus on CGT and oncology to capture high-growth markets.

Conclusion

The biopharma landscape in 2025 is characterized by rapid innovation, geopolitical shifts, and localized manufacturing surges. Companies that master AI-driven R&D, scale CGT production, and navigate regulatory complexities will lead the next era of drug development. Key recommendations include strengthening domestic manufacturing, forming strategic alliances, and investing in digital health to mitigate global uncertainties.